Praxis Precision Medicines jumps as FDA review timeline boosts ulixacaltamide outlook
Praxis Precision Medicines shares rose after momentum from a recent FDA milestone for ulixacaltamide in essential tremor. The FDA accepted the New Drug Application and set a PDUFA target action date of January 29, 2027, keeping traders focused on a potential first commercial launch.
1. What’s moving the stock today
Praxis Precision Medicines (PRAX) is trading higher as investors continue to re-price the company following the FDA’s acceptance of its New Drug Application (NDA) for ulixacaltamide HCl for essential tremor in adults. The regulatory acceptance established a clear review clock and reduced near-term uncertainty, helping support follow-through buying after the initial headline.
2. The key catalyst: FDA acceptance and review timeline
The FDA accepted the ulixacaltamide NDA for review and set a Prescription Drug User Fee Act (PDUFA) target action date of January 29, 2027. That timeline extends visibility for the next major binary event and gives the market a concrete date to anchor expectations around a potential approval and launch pathway. The acceptance has also been framed as a significant de-risking step given ulixacaltamide’s positioning in essential tremor and its prior Breakthrough Therapy Designation.
3. Near-term narrative support: conference spotlight and Street targets
Praxis has also been highlighting expanded analyses from its Phase 3 Essential3 program and broader CNS pipeline updates at the American Academy of Neurology (AAN) 2026 meeting (April 18–22, 2026). Separately, sell-side updates have kept the name active, including a recently published $510 price target from Needham, which investors are using as a reference point as PRAX trades around the mid-$300s.